Quality professionals do more than most people realize. In life sciences, that work carries a responsibility that is often easiest to overlook when products are moving, milestones are being met, and problems are being prevented… 

Investors backed the opportunity. Now the company has to prove it can execute. For emerging pharma, biotech, cell and gene therapy, and medical device companies, the next FDA milestone is not supported by capital alone.… 

FDA‘s March 2026 draft guidance on responding to Form 483 observations after drug CGMP inspections is worth reading closely. Not because it creates a new legally enforceable requirement. It does not. It matters because it… 

FDA’s new pilot for one day inspectional assessments is worth understanding clearly, because the actual results are more instructive than the headlines suggest. Here is what FDA reported as of late April 2026. The agency… 

FDA‘s March 2026 draft guidance on responding to Form 483 observations after drug CGMP inspections is worth reading closely. Not because it creates a new legally enforceable requirement. It does not. It matters because it… 

Here Is What the Results Show FDA’s new pilot for one day inspectional assessments is worth understanding clearly, because the actual results are more instructive than the headlines suggest. Here is what FDA reported as…